Komori
Tri Chemical Laboratories (4369) · RiskMitigated

Spread of COVID-19

First written in FY2020. 9 of 12 entries say "Restated". Latest entry: FY2024.

12entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q2 – FY2023-Q32020: 420202021: 420212022: 320222023: 020232024: 12024
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1252 companies write about · 1264 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1278 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024MitigatedAnnual report

    「During the current consolidated fiscal year, the Japanese economy saw the transition of COVID-19 to a Category V infectious disease and the normalization of economic activity progress, and the economy showed signs of a gradual recovery, but」

    The disclosure describes the transition of COVID-19 to a Category V infectious disease and the normalization of economic activity, indicating that conditions have eased from the previous focus on the spread of infection and voluntary restraints on activity.
  2. FY2023-Q3RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  3. FY2023-Q2RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  4. FY2023-Q1RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  5. FY2022-Q3RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  6. FY2022-Q2RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  7. FY2022-Q1RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  8. FY2021RestatedAnnual report

    「COVID-19 has not had a significant impact on performance for the current consolidated fiscal year, and accounting estimates have been prepared on the assumption that its impact will remain limited in the future. However, as the impact of the spread of COVID-19 remains subject to many uncertainties, the Group will continue to closely monitor developments.」

    While stating that there has been no significant impact on performance for the current fiscal year and that the future impact is assumed to be limited, the disclosure says that developments are being closely monitored because many uncertainties remain.
  9. FY2021-Q3RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  10. FY2021-Q2RestatedAnnual report

    「In addition, although the impact of COVID-19 on the Group's business activities is currently limited, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    While stating that the impact of the infectious disease on business activities is currently limited, the disclosure says that the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  11. FY2021-Q1MitigatedAnnual report

    「At present, the impact of COVID-19 on the Group's business activities is limited. However, the Group will continue to closely monitor the future impact of the disease on economic conditions in each country and on the supply chains of the Group and its customers.」

    The disclosure states that the impact on the Group's business activities is currently limited, while the future impact on the economies of individual countries and on the supply chains of the Group and its customers will continue to be closely monitored.
  12. FY2020First statedAnnual report

    「Since December 2019, cases of COVID-19 have continued to be reported around the world, including Japan, and the World Health Organization declared the disease a pandemic in March 2020. If the disease occurs and spreads within the group or among its business partners in the future, this could affect the group's financial position and operating performance.」

    The disclosure independently identifies the emergence and spread of COVID-19 and a deterioration in the global economy as new risks that could affect the business activities and performance of the group and its business partners.
Moved together

"Growth in Net Assets" moved the same way as this thread, in the same document, in 2 of its 12 moves.

2★1
  1. ★This thread
  2. 1Growth in Net Assets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tri Chemical Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Spread of COVID-19 | Tri Chemical Laboratories Inc. (4369) | Komori